Tokyo Tape
Sign in
← Taiko Pharmaceutical

Quarterly report · Q3

4574.TEDINET S100PJWU
Period2022-01-01 → 2022-09-30
Filed2022-11-11
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 33
MetricValuePeriodScopeSource row
Revenue¥3.4bn2022-01-01 → 2022-09-30Cons.Net sales
Revenue¥11.3bn2021-01-01 → 2021-12-31Cons.Net sales (5-year summary)
Revenue¥8.4bn2021-01-01 → 2021-09-30Cons.Net sales
Operating income−¥2.8bn2022-01-01 → 2022-09-30Cons.Operating income
Operating income−¥1.6bn2021-01-01 → 2021-09-30Cons.Operating income
Ordinary income−¥2.9bn2022-01-01 → 2022-09-30Cons.Ordinary income
Ordinary income−¥6.1bn2021-01-01 → 2021-12-31Cons.Ordinary income loss (5-year summary)
Ordinary income−¥2.4bn2021-01-01 → 2021-09-30Cons.Ordinary income
Profit before tax−¥3.2bn2022-01-01 → 2022-09-30Cons.Income before income taxes
Profit before tax−¥2.6bn2021-01-01 → 2021-09-30Cons.Income before income taxes
Net income (owners)−¥3.2bn2022-01-01 → 2022-09-30Cons.Profit loss attributable to owners of parent
Net income (owners)−¥9.6bn2021-01-01 → 2021-12-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)−¥1.9bn2021-01-01 → 2021-09-30Cons.Profit loss attributable to owners of parent
Net income−¥3.2bn2022-01-01 → 2022-09-30Cons.Profit loss
Net income−¥1.9bn2021-01-01 → 2021-09-30Cons.Profit loss
Total assets¥16.5bnat 2022-09-30Cons.Assets
Total assets¥22.5bnat 2021-12-31Cons.Assets
Total assets¥28.5bnat 2021-09-30Cons.Total assets (5-year summary)
Total liabilities¥6.7bnat 2022-09-30Cons.Liabilities
Total liabilities¥9.7bnat 2021-12-31Cons.Liabilities
Net assets / equity¥9.8bnat 2022-09-30Cons.Net assets
Net assets / equity¥12.8bnat 2021-12-31Cons.Net assets
Net assets / equity¥20.4bnat 2021-09-30Cons.Net assets (5-year summary)
Cash and deposits¥3.4bnat 2022-09-30Cons.Cash and deposits
Cash and deposits¥5.8bnat 2021-12-31Cons.Cash and deposits
EPS (basic)¥-72.972022-01-01 → 2022-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-8.82022-07-01 → 2022-09-30dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-220.522021-01-01 → 2021-12-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-44.792021-01-01 → 2021-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥9.752021-07-01 → 2021-09-30dCons.Basic earnings loss per share (5-year summary)
Equity ratio59.6%at 2022-09-30Cons.Equity to asset ratio (5-year summary)
Equity ratio56.8%at 2021-12-31Cons.Equity to asset ratio (5-year summary)
Equity ratio71.6%at 2021-09-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 26
SegmentItemPeriodValue
Reconciling Itemsreconcilingsegment profit2022-01-01 → 2022-09-30−¥893m
jpcrp040300-q3r_E22560-000Infection Control Businessreportable segmentrevenue2022-01-01 → 2022-09-30¥976m
jpcrp040300-q3r_E22560-000Infection Control Businessreportable segmentrevenue external2022-01-01 → 2022-09-30¥976m
jpcrp040300-q3r_E22560-000Infection Control Businessreportable segmentsegment profit2022-01-01 → 2022-09-30−¥1.8bn
jpcrp040300-q3r_E22560-000Other Business Linesreportable segmentrevenue2022-01-01 → 2022-09-30¥5m
jpcrp040300-q3r_E22560-000Other Business Linesreportable segmentrevenue external2022-01-01 → 2022-09-30¥5m
jpcrp040300-q3r_E22560-000Other Business Linesreportable segmentsegment profit2022-01-01 → 2022-09-30−¥14m
jpcrp040300-q3r_E22560-000Pharmaceuticals Businessreportable segmentrevenue2022-01-01 → 2022-09-30¥2.4bn
jpcrp040300-q3r_E22560-000Pharmaceuticals Businessreportable segmentrevenue external2022-01-01 → 2022-09-30¥2.4bn
jpcrp040300-q3r_E22560-000Pharmaceuticals Businessreportable segmentsegment profit2022-01-01 → 2022-09-30−¥42m
Total Of Reportable Segments And Otherssegment totalrevenue2022-01-01 → 2022-09-30¥3.4bn
Total Of Reportable Segments And Otherssegment totalrevenue external2022-01-01 → 2022-09-30¥3.4bn
Total Of Reportable Segments And Otherssegment totalsegment profit2022-01-01 → 2022-09-30−¥1.9bn
Reconciling Itemsreconcilingsegment profit2021-01-01 → 2021-09-30−¥1.1bn
jpcrp040300-q3r_E22560-000Infection Control Businessreportable segmentrevenue2021-01-01 → 2021-09-30¥5.3bn
jpcrp040300-q3r_E22560-000Infection Control Businessreportable segmentrevenue external2021-01-01 → 2021-09-30¥5.3bn
jpcrp040300-q3r_E22560-000Infection Control Businessreportable segmentsegment profit2021-01-01 → 2021-09-30−¥1.5bn
jpcrp040300-q3r_E22560-000Other Business Linesreportable segmentrevenue2021-01-01 → 2021-09-30¥5m
jpcrp040300-q3r_E22560-000Other Business Linesreportable segmentrevenue external2021-01-01 → 2021-09-30¥5m
jpcrp040300-q3r_E22560-000Other Business Linesreportable segmentsegment profit2021-01-01 → 2021-09-30−¥21m
jpcrp040300-q3r_E22560-000Pharmaceuticals Businessreportable segmentrevenue2021-01-01 → 2021-09-30¥3.0bn
jpcrp040300-q3r_E22560-000Pharmaceuticals Businessreportable segmentrevenue external2021-01-01 → 2021-09-30¥3.0bn
jpcrp040300-q3r_E22560-000Pharmaceuticals Businessreportable segmentsegment profit2021-01-01 → 2021-09-30¥1.0bn
Total Of Reportable Segments And Otherssegment totalrevenue2021-01-01 → 2021-09-30¥8.4bn
Total Of Reportable Segments And Otherssegment totalrevenue external2021-01-01 → 2021-09-30¥8.4bn
Total Of Reportable Segments And Otherssegment totalsegment profit2021-01-01 → 2021-09-30−¥506m

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 372
ItemContextValueUnit
Notes and accounts payable tradeCurrentQuarterInstant255000000JPY
Current portion of long term loans payablePrior1YearInstant923000000JPY
Current portion of long term loans payableCurrentQuarterInstant969000000JPY
Accounts payable otherPrior1YearInstant1270000000JPY
Accounts payable otherCurrentQuarterInstant473000000JPY
Income taxes payablePrior1YearInstant12000000JPY
Income taxes payableCurrentQuarterInstant13000000JPY
Provision for sales returnsPrior1YearInstant699000000JPY
Provision for sales returnsCurrentQuarterInstant－JPY
Refund liabilities clPrior1YearInstant－JPY
Refund liabilities clCurrentQuarterInstant196000000JPY
Provision for bonusesPrior1YearInstant149000000JPY
Provision for bonusesCurrentQuarterInstant20000000JPY
Other clPrior1YearInstant955000000JPY
Other clCurrentQuarterInstant252000000JPY
Current liabilitiesPrior1YearInstant4320000000JPY
Current liabilitiesCurrentQuarterInstant2183000000JPY
Long term loans payablePrior1YearInstant3760000000JPY
Long term loans payableCurrentQuarterInstant2980000000JPY
Long term accounts payable otherPrior1YearInstant549000000JPY
Long term accounts payable otherCurrentQuarterInstant549000000JPY
Net defined benefit liabilityPrior1YearInstant805000000JPY
Net defined benefit liabilityCurrentQuarterInstant654000000JPY
Other nclPrior1YearInstant292000000JPY
Other nclCurrentQuarterInstant287000000JPY
Noncurrent liabilitiesPrior1YearInstant5407000000JPY
Noncurrent liabilitiesCurrentQuarterInstant4471000000JPY
LiabilitiesPrior1YearInstant9728000000JPY
LiabilitiesCurrentQuarterInstant6655000000JPY
Capital stockPrior1YearInstant1201000000JPY
Capital stockCurrentQuarterInstant1201000000JPY
Capital surplusPrior1YearInstant1648000000JPY
Capital surplusCurrentQuarterInstant1642000000JPY
Retained earningsPrior1YearInstant10134000000JPY
Retained earningsCurrentQuarterInstant6952000000JPY
Treasury stockPrior1YearInstant-388000000JPY
Treasury stockCurrentQuarterInstant-348000000JPY
Shareholders equityPrior1YearInstant12596000000JPY
Shareholders equityCurrentQuarterInstant9447000000JPY
Foreign currency translation adjustmentPrior1YearInstant210000000JPY
Foreign currency translation adjustmentCurrentQuarterInstant371000000JPY
Valuation and translation adjustmentsPrior1YearInstant210000000JPY
Valuation and translation adjustmentsCurrentQuarterInstant371000000JPY
Subscription rights to sharesPrior1YearInstant0JPY
Subscription rights to sharesCurrentQuarterInstant0JPY
Net assetsPrior1YearInstant12807000000JPY
Net assetsCurrentQuarterInstant9819000000JPY
Liabilities and net assetsPrior1YearInstant22535000000JPY
Liabilities and net assetsCurrentQuarterInstant16474000000JPY
Net salesPrior1YTDDuration8355000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2021-12-31pass
balance sheet identityconsolidated 2022-09-30pass
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2021-12-31pass
statement vs summary · net assetsconsolidated 2022-09-30pass
statement vs summary · net income attributable to parentconsolidated 2021-01-01/2021-09-30pass
statement vs summary · net income attributable to parentconsolidated 2022-01-01/2022-09-30pass
statement vs summary · revenueconsolidated 2021-01-01/2021-09-30pass
statement vs summary · revenueconsolidated 2022-01-01/2022-09-30pass
statement vs summary · total assetsconsolidated 2021-12-31pass
statement vs summary · total assetsconsolidated 2022-09-30pass